Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Details 2)

v3.19.1
Stockholders' Equity (Details 2)
12 Months Ended
Dec. 31, 2018
$ / shares
shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Stock Options, Total Outstanding | shares 5,488,282
Stock Options, Number Exercisable | shares 4,384,294
Grant Price From 0.05 To 2.02 [Member]  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 0.05
Stock Options, Grant Price, Maximum 2.02
Stock Options, Weighted Average Exercise Price $ 0.90
Stock Options, Total Outstanding | shares 3,533,282
Stock Options, Number Exercisable | shares 3,432,344
Stock Options, Weighted Average Remaining Contractual Term 6 years 2 months 16 days
Grant Price From 2.40 To 4.60 [Member]  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 2.40
Stock Options, Grant Price, Maximum 4.60
Stock Options, Weighted Average Exercise Price $ 2.87
Stock Options, Total Outstanding | shares 1,202,000
Stock Options, Number Exercisable | shares 627,208
Stock Options, Weighted Average Remaining Contractual Term 8 years 4 months 17 days
Grant Price From 5.30 To 8.86 [Member]  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 5.30
Stock Options, Grant Price, Maximum 8.86
Stock Options, Weighted Average Exercise Price $ 6.52
Stock Options, Total Outstanding | shares 753,000
Stock Options, Number Exercisable | shares 324,742
Stock Options, Weighted Average Remaining Contractual Term 9 years 4 months 6 days